一分钟看懂
这是一项关于胃癌的II 期研究，登记的药物或干预包括Disitamab Vedotin；Sintilimab；S-1；Trastuzumab；Oxaliplatin；Capecitabine；5-FU；Cisplatin，当前状态为招募中。登记地点显示中国郑州、滨州、东营、济南等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Disitamab Vedotin；Sintilimab；S-1；Trastuzumab；Oxaliplatin；Capecitabine；5-FU；Cisplatin · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of Zhengzhou University · 郑州
- Binzhou Medical University Hospital · 滨州
- Shengli Oilfield Central Hospital · 东营
- Shandong Provincial Hospital Affiliated to Shandong First Medical University · 济南
- Shandong Provincial Third Hospital · 济南
- Shandong Univerisity Qilu Hospital · 济南
- Jinan Third People's Hospital · 济南
- Affiliated Hospital of Jining Medical College · 济宁
- Liaocheng People's Hospital · 聊城
- Linyi Cancer Hospital · 临沂
- Qilu Hospital of Shandong University(Qingdao) · 青岛
- The Affiliated Hospital of Qingdao University · 青岛
- Taian City Central Hospital · 泰安
- The Second Affiliated Hospital of Shandong First Medical University · 泰安
- Tengzhou Central People's Hospital · 滕州
- Weifang Hospital of Traditional Chinese Medicine · 潍坊
- Yantai Yuhuangding Hospital · 烟台
- Yantaishan Hospital · 烟台
- Zibo Central Hospital · 淄博
- Zibo First People's Hospital · 淄博
公开的入选条件
- 1. Aged18-80 years, gender is not limited;
- 2. Pathologically confirmed locally advanced gastric or gastroesophageal junction adenocarcinoma that is inoperable or has distant metastasis;
- 3. HER2-Positive (IHC3+or IHC2+/FISH+) ;
- 4. Has at least 1 measurable lesion as determined by RECIST 1.1;
- 5. There is no systematic treatment in the past, or the patient has received neoadjuvant/adjuvant chemotherapy, but the disease progresses or relapses more than 6 months after the end of treatment;
- 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- 7. Adequate organ function;
- 8. The life expectancy is at least 3 months;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06730373；登记信息更新于 2026-09-15。